Enanta Pharmaceuticals Inc (ENTA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $320.09M
Last updated: Nov 17, 2026 at 11:05 AM ET
Enanta Pharmaceuticals Inc (ENTA) Competitors
The companies most similar to Enanta Pharmaceuticals are Prothena Corporation (PRTA), Entera Bio (ENTX) and Entrada Therapeutics (TRDA). By market cap, Enanta Pharmaceuticals ranks 9th of the 13 companies on this page; Entera Bio (ENTX) is the largest at $541.57M.
Peer Comparison
ENTA's revenue growth of -21.6% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals (ENTA) | $320.09M | N/A | 4.8x | -96.9% | N/A | -21.6% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| Entera Bio Ltd (ENTX) | $541.57M | N/A | N/A | 0.0% | -8.5% | -100.0% | 0.00% |
| Entrada Therapeutics Inc (TRDA) | $199.28M | N/A | 53.3x | 0.0% | -69.7% | -43.9% | 0.00% |
| enGene Therapeutics Inc. (ENGN) | $161.51M | N/A | N/A | 0.0% | -42.2% | 0.0% | 0.00% |
| Tectonic Therapeutic, Inc. (TECX) | $413.27M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Editas Medicine Inc (EDIT) | $334.92M | N/A | 5.6x | -145.0% | -42.3% | 37.4% | 0.00% |
| Regenxbio Inc (RGNX) | $505.18M | N/A | 3.1x | -113.9% | N/A | -69.2% | 0.00% |
| PepGen Ltd (PEPG) | $410.98M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | $387.16M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Arcturus Therapeutics Holdings Inc (ARCT) | $240.96M | N/A | 7.7x | -285.9% | N/A | 6.7% | 0.00% |
| Vanda Pharmaceuticals Inc (VNDA) | $241.27M | N/A | 1.0x | -119.9% | -84.7% | 24.1% | 0.00% |
| Peer median | $396.88M | N/A | 6.7x | 0.0% | -42.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Enanta Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| Entera Bio Ltd (ENTX) | Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies... | ENTX competitors |
| Entrada Therapeutics Inc (TRDA) | Entrada Therapeutics Inc. (TRDA) is a forward-thinking biotechnology company focused on creating innovative therapies for severe diseases characterized by... | TRDA competitors |
| enGene Therapeutics Inc. (ENGN) | enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery... | ENGN competitors |
| Tectonic Therapeutic, Inc. (TECX) | Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel... | TECX competitors |
| Editas Medicine Inc (EDIT) | Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. | EDIT competitors |
| Regenxbio Inc (RGNX) | REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable... | RGNX competitors |
| PepGen Ltd (PEPG) | PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious... | PEPG competitors |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies... | CTNM competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Arcturus Therapeutics Holdings Inc (ARCT) | Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. | ARCT competitors |
| Vanda Pharmaceuticals Inc (VNDA) | Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. | VNDA competitors |
Frequently Asked Questions About ENTA
Who are Enanta Pharmaceuticals' main competitors?
The companies most similar to Enanta Pharmaceuticals include Prothena Corporation (PRTA), Entera Bio (ENTX), Entrada Therapeutics (TRDA), enGene Therapeutics (ENGN) and Tectonic Therapeutic (TECX), listed from the closest match.
Who is Enanta Pharmaceuticals' biggest competitor?
Entera Bio (ENTX) is the largest of the similar companies at $541.57M; Prothena Corporation (PRTA) is the closest match by business profile, size, sector and industry.
How does ENTA stock compare with its competitors?
ENTA's P/S is 4.8x against a peer median of 6.7x; its net margin is -96.9% against a peer median of 0.0%.
Which of Enanta Pharmaceuticals' competitors pays a higher dividend?
Enanta Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Enanta Pharmaceuticals bigger than its competitors?
No. Enanta Pharmaceuticals is 9th by market cap among the 13 companies on this page; the largest is Entera Bio (ENTX) at $541.57M.
ENTA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors